Budget Impact of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (nAMD) in Ireland
Author(s)
de Greeff J1, Goodwin M2
1Roche Nederland B.V., Woerden, UT, Netherlands, 2Roche Products Ireland Limited, Dublin 24, D, Ireland
Presentation Documents
OBJECTIVES: Age-related macular degeneration is the leading cause of blindness in the over 50's population in Ireland. The objective of this study was to assess the budget impact of faricimab, a novel treatment for neovascular Age-related Macular Degeneration (nAMD), on the Health Service Executive (HSE) in Ireland.
METHODS: A budget impact model estimated the additive cost associated with the introduction of faricimab into clinical practice for nAMD in Ireland over a 5-year time horizon.
Epidemiological data and treatment market shares were obtained from available literature. Model inputs included patient population based on national epidemiological data, treatment regimen, drug costs and administration costs. A treat-and-extend regimen was reflected in the model, which is characteristic of clinical practice in Ireland. Cost offsets resulting from reduced treatment burden were also considered. A bilateral rate of 1.2 was applied to account for patients receiving intravitreal treatment (IVT) in both eyes.RESULTS: Gross Drug-Budget Impact: The total cost associated with faricimab over 5 years amounted to €11,940,626 (excluding VAT) direct to health system costs.
Net Drug-Budget Impact: The net impact over the 5 year time horizon was -€2,775,449 (excluding VAT).CONCLUSIONS: Faricimab, administered as a treat-and-extend regimen, not only provides clinical benefits but also has significant economic impact within the Irish healthcare system. By allowing safe extension of treatment intervals without compromising efficacy, faricimab reduces the treatment burden on patients and caregivers whilst also optimising healthcare resource utilisation, leading to long-term cost savings.
It is noted that our analysis does not account for additional indirect savings, such as improved patient quality of life and productivity gains. Further research and real-world evidence are warranted to validate these findings.Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
EE422
Topic
Economic Evaluation, Health Policy & Regulatory
Topic Subcategory
Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Public Spending & National Health Expenditures, Reimbursement & Access Policy
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Sensory System Disorders (Ear, Eye, Dental, Skin)